Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-444P is a *small nuclear RNA pseudogene* found in the human genome[2][4][5]. It is derived from U6 snRNA, which is a core component of the spliceosomal RNA machinery required for mRNA splicing[1][3]. However, RNU6-444P itself is classified as a *processed pseudogene*—it is a noncoding, nonfunctional relic in the genome resulting from L1-mediated retrotransposition, and does not produce any functional RNA or protein[5]. Functional U6 snRNA participates in spliceosome assembly and catalysis, but pseudogene copies like RNU6-444P do not contribute to the splicing process or other biological functions[1][3][5]. There are no known associations between RNU6-444P and human diseases, drug interactions, or use as a biomarker. Thus, for research or clinical targeting purposes, RNU6-444P should *not* be considered a valid molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 444, pseudogene (RNU6-444P).